We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Sponsor content
39 result(s) found, displaying 11 to 20
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for SPIKEVAX BIVALENT ORIGINAL/OMICRON BA.4-5 (elasomeran/davesomeran) COVID-19 VACCINE 0.1 mg/mL suspension for injection vial-single dose.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for SPIKEVAX BIVALENT ORIGINAL/OMICRON BA.4-5 (elasomeran/davesomeran) COVID-19 VACCINE 0.1 mg/mL suspension for injection pre-filled syringe.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for SPIKEVAX BIVALENT ORIGINAL/OMICRON BA.4-5 (elasomeran/davesomeran) COVID-19 VACCINE 0.1 mg/mL suspension for injection vial.
-
Australian public assessment report (AusPar)Spikevax XBB.1.5 (andusomeran) has been approved for the prevention of COVID-19 caused by SARS-CoV-2 in individuals 12 years of age and older.
-
Australian public assessment report (AusPar)Spikevax (Elasomeran/davesomeran), a vaccine, has transitioned from provisional to full registration. Spikevax is for the prevention of coronavirus disease 2019 caused by SARS-CoV-2.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for SPIKEVAX (elasomeran) COVID-19 VACCINE 0.1 mg/mL suspension for injection vial - multidose.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for SPIKEVAX (elasomeran) COVID-19 VACCINE 0.1 mg/mL suspension for injection pre-filled syringe.
-
Australian public assessment report (AusPar)New AusPAR for Spikevax (elasomeran) for the prevention of COVID-19 caused by SARS-CoV-2.
-
Designation or determinationPriority review
-
Australian public assessment report (AusPar)AusPAR for SPIKEVAX BIVALENT ORIGINAL/OMICRON BA.4-5 (elasomeran/davesomeran) as booster dose for active immunisation to prevent COVID-19